Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
2 May 23
ARS
2022 FY
Annual report to shareholders
2 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
8 Mar 22
Current reports
8-K
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
21 Mar 24
8-K
Other Events
14 Mar 24
8-K
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
5 Mar 24
8-K
Regulation FD Disclosure
8 Dec 23
8-K
Other Events
5 Dec 23
8-K
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Corporate Presentation November 2023
8 Nov 23
8-K
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results
6 Nov 23
8-K
Aquestive Therapeutics Completes $45 Million Debt Refinancing
2 Nov 23
8-K
Aquestive Therapeutics Provides Business Update
10 Oct 23
8-K
Other Events
20 Sep 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
21 Mar 24
424B5
Prospectus supplement for primary offering
19 Mar 24
S-8
Registration of securities for employees
12 Feb 24
424B3
Prospectus supplement
2 Oct 23
S-3
Shelf registration
20 Sep 23
S-8
Registration of securities for employees
9 Aug 23
S-8
Registration of securities for employees
18 Jan 23
424B5
Prospectus supplement for primary offering
7 Sep 22
424B5
Prospectus supplement for primary offering
8 Jun 22
424B5
Prospectus supplement for primary offering
13 Apr 22
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
23 May 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
5 May 21
DEF 14A
Definitive proxy
5 May 21
DEFA14A
Additional proxy soliciting materials
4 Jun 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
27 Sep 23
UPLOAD
Letter from SEC
25 Sep 23
CT ORDER
Confidential treatment order
22 Sep 21
EFFECT
Notice of effectiveness
6 Apr 21
CORRESP
Correspondence with SEC
1 Apr 21
UPLOAD
Letter from SEC
31 Mar 21
EFFECT
Notice of effectiveness
20 Jan 21
CORRESP
Correspondence with SEC
14 Jan 21
UPLOAD
Letter from SEC
13 Jan 21
Ownership
4
Alexander Mark Schobel
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Daniel Barber
12 Mar 24
4
Peter E. Boyd
12 Mar 24
4
LORI J BRAENDER
12 Mar 24
4
A ERNEST TOTH JR
12 Mar 24
4
Stephen Wargacki
12 Mar 24
4
Cassie Jung
12 Mar 24
4
Alexander Mark Schobel
12 Mar 24
4
LORI J BRAENDER
11 Mar 24